JC Master Updates | Attorney Bie Jiajun of JC Master (Taizhou) was invited to deliver a presentation on “Analysis of Civil Legal Liability in Disputes over Adverse Events in Clinical Drug Trials and Strategies for Prevention and Control.”

To further standardize clinical trial practices and help relevant stakeholders accurately grasp the key legal risks in this field, thereby effectively enhancing their practical capabilities in risk prevention and compliance management, the “Clinical Trial Legal Risk Management Salon,” co‑hosted by the Taizhou Pharmaceutical Society and the Taizhou Lawyers Association and supported by Yangtze River Pharmaceutical Group, was recently held at the Taizhou Pharmaceutical Society’s Member Activity Center. Attorney Bie Jiajun of JC Master (Taizhou) was invited to deliver a keynote presentation.

Attorney Bi delivered a presentation titled “An Analysis of Civil Legal Liability in Disputes Arising from Adverse Events in Clinical Drug Trials and Corresponding Prevention and Control Strategies.” Drawing on recent judicial precedents, he examined the principles of liability and emerging trends in cases involving torts and contractual disputes triggered by adverse events. He focused on key aspects such as the legal validity of informed consent forms, the assessment of protocol compliance, and the preservation of evidence, and offered practical recommendations for establishing mechanisms for risk early warning, emergency response, and dispute resolution. Participants unanimously praised the session, noting that it effectively helps enterprises manage risks and holds significant practical value.

JC Master (Taizhou) Law Office will deepen its expertise in pharmaceutical‑related legal services, adhering to a philosophy of professionalism and pragmatic success. By leveraging regulatory analysis and practical experience, the office will help industry stakeholders fortify their compliance frameworks, mitigate legal risks, and drive innovative development, consistently serving as a steadfast legal guardian for the steady advancement of the pharmaceutical sector.